MX2017014859A - Metodos y composiciones para diagnosticar o detectar canceres de pulmon. - Google Patents

Metodos y composiciones para diagnosticar o detectar canceres de pulmon.

Info

Publication number
MX2017014859A
MX2017014859A MX2017014859A MX2017014859A MX2017014859A MX 2017014859 A MX2017014859 A MX 2017014859A MX 2017014859 A MX2017014859 A MX 2017014859A MX 2017014859 A MX2017014859 A MX 2017014859A MX 2017014859 A MX2017014859 A MX 2017014859A
Authority
MX
Mexico
Prior art keywords
methods
compositions
mirna
diagnosing
gene
Prior art date
Application number
MX2017014859A
Other languages
English (en)
Inventor
C Showe Louise
K Showe Michael
V Kossenkov Andrei
Original Assignee
Wistar Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Inst filed Critical Wistar Inst
Publication of MX2017014859A publication Critical patent/MX2017014859A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Data Mining & Analysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Bioethics (AREA)
  • Artificial Intelligence (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Evolutionary Computation (AREA)
  • Software Systems (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Primary Health Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Una composición de múltiples analitos para el diagnóstico de cáncer de pulmón o enfermedad pulmonar que comprende un ligando que se selecciona de una secuencia de ácido nucleico, polinucleótido u oligonucleótido capaz de formar complejos especí­ficamente con, hibridar o identificar un transcripto genótico de ARNm a partir de una muestra de sangre de un mamí­fero y un ligando adicional que se selecciona de una secuencia de ácido nucleico, polinucleótido u oligonucleótido capaz de formar complejos especí­ficamente con, hibridar o identificar un miARN de un gen de una muestra de sangre de un mamí­fero. Cada ligando y ligando adicional se une a un transcripto genótico o miARN diferente y los transcriptos gónicos y miARN identificados forman un perfil caracterí­stico de una etapa de cáncer de pulmón o enfermedad pulmonar. Se describen métodos para utilizar esta composición para el diagnóstico y evaluación y los métodos para desarrollar dichas composiciones.
MX2017014859A 2015-05-19 2016-05-19 Metodos y composiciones para diagnosticar o detectar canceres de pulmon. MX2017014859A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562163766P 2015-05-19 2015-05-19
PCT/US2016/033232 WO2016187404A1 (en) 2015-05-19 2016-05-19 Methods and compositions for diagnosing or detecting lung cancers

Publications (1)

Publication Number Publication Date
MX2017014859A true MX2017014859A (es) 2018-07-06

Family

ID=57320853

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014859A MX2017014859A (es) 2015-05-19 2016-05-19 Metodos y composiciones para diagnosticar o detectar canceres de pulmon.

Country Status (13)

Country Link
US (2) US20180142303A1 (es)
EP (1) EP3298182A4 (es)
JP (1) JP2018524972A (es)
KR (1) KR20180009762A (es)
CN (1) CN107709636A (es)
AU (1) AU2016263590A1 (es)
BR (1) BR112017024688A2 (es)
CA (1) CA2985683A1 (es)
IL (1) IL255659A (es)
MX (1) MX2017014859A (es)
RU (1) RU2017143008A (es)
SG (1) SG10201910412QA (es)
WO (1) WO2016187404A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11535895B2 (en) 2017-04-06 2022-12-27 University Of Maryland, Baltimore Methods of detecting lung cancer
US10846367B2 (en) * 2017-09-15 2020-11-24 Case Western Reserve University University Predicting recurrence in early stage non-small cell lung cancer (NSCLC) with integrated radiomic and pathomic features
KR102097794B1 (ko) 2018-09-17 2020-04-06 차의과학대학교 산학협력단 신규한 miRNA smR-167 및 폐암 예방 또는 치료를 위한 이의 용도
CN109712717A (zh) * 2018-12-27 2019-05-03 湖南大学 一种基于miRNA-基因调控模块的癌症相关MicroRNA识别方法
EP3938536A4 (en) * 2019-03-12 2023-03-08 Crown Bioscience (Suzhou) Inc. METHODS AND COMPOSITIONS FOR IDENTIFICATION OF TUMOR MODELS
CN110669104B (zh) * 2019-10-30 2021-11-05 上海交通大学 一组来源于人外周血单核细胞的标志物及其应用
CN111118164A (zh) * 2020-03-02 2020-05-08 遵义市第一人民医院 一种用于肿瘤早期筛查和诊断的标志物、试剂盒及检测方法
CN112415199B (zh) * 2020-11-20 2023-09-08 四川大学华西医院 Cetp检测试剂在制备肺癌筛查试剂盒中的用途
WO2022127717A1 (zh) * 2020-12-17 2022-06-23 广州市基准医疗有限责任公司 用于检测肺结节良恶性的甲基化分子标记物或其组合和应用
CN112635063B (zh) * 2020-12-30 2022-05-24 华南理工大学 一种肺癌预后综合预测模型、构建方法及装置
CN115527614B (zh) * 2022-04-12 2023-12-26 陈恩国 一种肺动脉高压的基因表达分类器
CN116823818B (zh) * 2023-08-28 2023-11-07 四川省肿瘤医院 基于三维影像组学特征的肺结节识别系统和方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101111768A (zh) * 2004-11-30 2008-01-23 维里德克斯有限责任公司 肺癌预后
EP2502630B1 (en) * 2006-01-05 2015-03-11 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
US8476420B2 (en) * 2007-12-05 2013-07-02 The Wistar Institute Of Anatomy And Biology Method for diagnosing lung cancers using gene expression profiles in peripheral blood mononuclear cells
US20100055689A1 (en) * 2008-03-28 2010-03-04 Avrum Spira Multifactorial methods for detecting lung disorders
WO2010054233A1 (en) * 2008-11-08 2010-05-14 The Wistar Institute Of Anatomy And Biology Biomarkers in peripheral blood mononuclear cells for diagnosing or detecting lung cancers
US20110251086A1 (en) * 2008-12-10 2011-10-13 Joke Vandesompele Neuroblastoma prognostic multigene expression signature
EP2239675A1 (en) * 2009-04-07 2010-10-13 BIOCRATES Life Sciences AG Method for in vitro diagnosing a complex disease
JP5808349B2 (ja) * 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー
EP2505663A1 (en) * 2011-03-30 2012-10-03 IFOM Fondazione Istituto Firc di Oncologia Molecolare A method to identify asymptomatic high-risk individuals with early stage lung cancer by means of detecting miRNAs in biologic fluids
CN103492590A (zh) * 2011-02-22 2014-01-01 卡里斯生命科学卢森堡控股有限责任公司 循环生物标志物
EP2885425B1 (en) * 2012-08-20 2017-07-26 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Expression of protein-coding and noncoding genes as prognostic classifiers in early stage lung cancer
CA2895133A1 (en) * 2012-12-13 2014-06-19 Baylor Research Institute Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis
US20150072890A1 (en) * 2013-09-11 2015-03-12 20/20 Gene Systems, Inc. Methods and compositions for aiding in the detection of lung cancer

Also Published As

Publication number Publication date
WO2016187404A1 (en) 2016-11-24
IL255659A (en) 2018-01-31
RU2017143008A3 (es) 2020-01-29
EP3298182A4 (en) 2019-01-02
US20200131586A1 (en) 2020-04-30
CA2985683A1 (en) 2016-11-24
AU2016263590A1 (en) 2017-11-30
EP3298182A1 (en) 2018-03-28
US20180142303A1 (en) 2018-05-24
KR20180009762A (ko) 2018-01-29
SG10201910412QA (en) 2020-01-30
BR112017024688A2 (pt) 2019-02-12
RU2017143008A (ru) 2019-06-20
CN107709636A (zh) 2018-02-16
JP2018524972A (ja) 2018-09-06

Similar Documents

Publication Publication Date Title
MX2017014859A (es) Metodos y composiciones para diagnosticar o detectar canceres de pulmon.
Li et al. MicroRNA-25 promotes gastric cancer migration, invasion and proliferation by directly targeting transducer of ERBB2, 1 and correlates with poor survival
Anfossi et al. Clinical utility of circulating non-coding RNAs—an update
Anfossi et al. High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer
Jinushi et al. Low expression levels of micro RNA‐124‐5p correlated with poor prognosis in colorectal cancer via targeting of SMC 4
Thiel et al. Gastric cancer: basic aspects
SG10201908277TA (en) Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas)
MX2022012384A (es) Composiciones y metodos para cribar mutaciones en el cancer de tiroides.
WO2013107459A3 (en) Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples
WO2014144657A3 (en) Compositions and methods for cancer prognosis
JP2017523810A5 (es)
Izquierdo et al. Prognostic value of microRNA expression pattern in upper tract urothelial carcinoma
Chen et al. Combined downregulation of microRNA-133a and microRNA-133b predicts chemosensitivity of patients with esophageal squamous cell carcinoma undergoing paclitaxel-based chemotherapy
WO2009057113A3 (en) Diagnosis and prognosis of specific cancers by means of differential detection of micro-rnas/mirnas
Ning et al. Characterization of the Merkel cell carcinoma miRNome
MX358117B (es) Métodos y ácidos nucleicos para determinar el pronóstico de un sujeto con cáncer.
Odenthal et al. Serum micro RNA profiles as prognostic/predictive markers in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction
WO2013148147A8 (en) Dna methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
WO2019094780A3 (en) Non-coding rna for detection of cancer
El-Halawany et al. Investigating the pretreatment miRNA expression patterns of advanced hepatocellular carcinoma patients in association with response to TACE treatment
Sarlinova et al. miR-21, miR-221 and miR-150 are deregulated in peripheral blood of patients with colorectal cancer
Albonico et al. The expression ratio of miR-17-5p and miR-155 correlates with grading in canine splenic lymphoma
WO2012131670A3 (en) Methods for lung cancer clasification
WO2016034715A3 (fr) Methode de prediction de l'evolution clinique du cancer colorectal
EP3825416A3 (en) Gene expression profiles associated with sub-clinical kidney transplant rejection